Therapeutic method and medicament for HTLV-1 associated myelopathy
View Patent ↗The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.
1. A therapeutic method, comprising reducing expression level of a cytokine produced by a human T cell leukemia virus type-1 (HTLV-1)-infected cell in a HTLV-1 associated myelopathy (HAM) patient or an asymptomatic HTLV-1 carrier (AC), by administering an anti-human CC-chemokine receptor 4 (CCR4) antibody to the HAM patient or the AC.
2. The therapeutic method according to claim 1 , comprising reducing HTLV-1 virus-infected cells.
3. The therapeutic method according to claim 1 , comprising reducing the amount of HTLV-1 proviral DNA in the HAM patients.
4. The therapeutic method according to claim 1 , comprising reducing cell proliferation of the HTLV-1 virus-infected cell.
5. The therapeutic method according to claim 1 , wherein the HTLV-1 virus-infected cell is CCR4 + T cell.
6. The therapeutic method according to claim 1 , wherein the cytokine is any one selected from the group consisting of interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), interleukin (IL)-2 (IL-2), IL-6, IL-10 and IL-17.
7. The therapeutic method according to claim 1 , further comprising administering one or more of an immunosuppressant and an anti-viral agent.
8. The therapeutic method according to claim 7 , wherein the immunosuppressant is selected from the group consisting of prednisolone, methylprednisolone, dexamethasone, betamethasone, azathioprine, cyclosporine, tacrolimus, JAK inhibitor, NFκB inhibitor, and a combination thereof.
9. The therapeutic method according to claim 1 , further comprising administering a low dose of an immunosuppressant.
10. A method for reducing an expression level of a cytokine produced by a human T cell leukemia virus type-1 (HTLV-1)-infected cell in a HTLV-1 associated myelopathy (HAM) patient or an asymptomatic HTLV-1 carrier (AC), by administering an anti-human CC-chemokine receptor 4 (CCR4) antibody to the HAM patient or the AC.
11. The method according to claim 10 , comprising reducing HTLV-1 virus-infected cells.
12. The method according to claim 10 , comprising reducing an amount of HTLV-1 proviral DNA in the HAM patient.
13. The method according to claim 10 , comprising reducing cell proliferation of the HTLV-1 virus-infected cell.
14. The method according to claim 10 , wherein the HTLV-1 virus-infected cell is CCR4 + T cell.
15. The method according to claim 10 , wherein the cytokine is any one selected from the group consisting of IFN-γ, TNF-α, IL-2, IL-6, IL-10 and IL-17.
16. The method according to claim 10 , further comprising administering one or more of an immunosuppressant and an anti-viral agent.
17. The method according to claim 16 , wherein the immunosuppressant is any one selected from the group consisting of prednisolone, methylprednisolone, dexamethasone, betamethasone, azathioprine, cyclosporine, tacrolimus, JAK inhibitor, NFκB inhibitor, and a combination thereof.
18. The method according to claim 10 , further comprising administering a low dose of an immunosuppressant.